Holen Sie sich die Stockscreener-App
102.69
1.00%
1.065
Schlusskurs vom Vortag:
$101.62
Offen:
$102.24
24-Stunden-Volumen:
374.59K
Relative Volume:
0.73
Marktkapitalisierung:
$4.29B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-109.24
EPS:
-0.94
Netto-Cashflow:
-
1W Leistung:
+2.57%
1M Leistung:
+51.30%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$100.39
$107.95
1-Wochen-Bereich:
$99.53
$107.95
52-Wochen-Spanne:
$32.00
$117.71
Veradermics Inc Stock (MANE) Company Profile
Firmenname
Veradermics Inc
Sektor
Branche
Telefon
228.372.3376
Adresse
470 JAMES STREET, NEW HAVEN
Compare MANE vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MANE
Veradermics Inc
|
102.77 | 4.25B | 0 | 0 | 0 | -0.94 |
VRTX
Vertex Pharmaceuticals Inc
|
436.88 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.94 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.98 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.22 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.85 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veradermics Inc Stock (MANE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | Citigroup | Buy |
| 2026-03-02 | Eingeleitet | Jefferies | Buy |
| 2026-03-02 | Eingeleitet | Leerink Partners | Outperform |
Veradermics Inc Aktie (MANE) Neueste Nachrichten
Veradermics Incorporated (MANE) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
MANE Stock Price, Quote & Chart | VERADERMICS INC (NYSE:MANE) - ChartMill
10 Best Performing NYSE Stocks So Far in 2026 - Insider Monkey
Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts - Yahoo Finance
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026 - Insider Monkey
MANE News | VERADERMICS INC (NYSE:MANE) - ChartMill
Veradermics Is Maintained at Buy by Citigroup - Moomoo
Veradermics Price Target Raised to $135.00/Share From $120.00 by Citigroup - Moomoo
SR ONE CAPITAL MANAGEMENT, LP's Veradermics Inc(MANE) Holding History - GuruFocus
Viking Global-affiliates hold 1.69M Veradermics shares (MANE) - Stock Titan
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO - Yahoo Finance
Jefferies Maintains Veradermics(MANE.US) With Buy Rating, Raises Target Price to $138 - Moomoo
Veradermics (MANE) price target increased by 39.48% to 128.52 - MSN
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium - Business Wire
Can Veradermics Rally on Clinical Progress in Biotech Index? - Kalkine Media
Veradermics: Q1 Earnings Snapshot - KTVB
Veradermics 1Q 2026: Revenue ($27.82M), Net income ($30.01M), EPS ($1.32) — 10-Q Summary - TradingView
Veradermics (NYSE: MANE) posts Q1 2026 loss, funding runway into 2030 - Stock Titan
Veradermics Announces Positive Phase 2/3 Results for Oral Hair Loss Treatment VDPHL01, Raises $766.8M to Fund Operations Into 2030 - Minichart
Veradermics: Cash, Cash Equivalents, and Marketable Securities Totaled $390.8M as of March 31 >MANE - Moomoo
New Haven-based drug developer has raised $766.8M so far in ‘26 - Hartford Business Journal
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Veradermics (NYSE: MANE) boosts cash with $766.8M raise, advances VDPHL01 - Stock Titan
Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, vs. FactSet Est of $22.9M Loss - marketscreener.com
Earnings Flash (MANE) Veradermics Posts Q1 Net Loss $27.2M, Vs. FactSet Est of $22.9M Loss - Moomoo
Veradermics, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MANE SEC FilingsVERADERMICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Citi Remains Bullish on Veradermics, Incorporated (MANE) - Yahoo Finance
Citadel group reports 1.87M shares in Veradermics (MANE) - Stock Titan
Veradermics prices upsized $384M public offering and $30M private placement at $100/share - MSN
Suvretta-linked funds gain 300,000 MANE pre-funded warrants via awards - Stock Titan
Longitude group discloses 4.65M Veradermics (MANE) shares owned - Stock Titan
Dr. Brian Liu Discloses Investment at Veradermics, Inc with 0.2% Stake - TradingView
Seven Fleet (NASDAQ: MANE) files 13D on Veradermics 0.2% equity stake - Stock Titan
Seven Fleet discloses 80,000 Veradermics (MANE) shares in Form 3 - Stock Titan
Veradermics shares jump 17% on promising hair loss trial results - MSN
Experimental hair loss pill just cleared a major hurdle — when it could hit shelves - New York Post
Veradermics Inc Video Interviews. Director Interviews for MANE.US. Veradermics Inc Media. - London South East
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill - Yahoo Finance
The week in pharma: action, reaction and insight – week to May 1, 2026 - The Pharma Letter
Veradermics, Inc. Securities Purchase Agreement and Pre-Funded Warrant Details (May 2026) - Minichart
Three biotechs raise $850M+ in upsized IPOs, gain in aftermarket: Public Equity Report - biocentury.com
Veradermics Raises $30 Million in Private Pre-Funded Warrant Deal With Suvretta Affiliates - TradingView
[8-K] Veradermics, Inc Reports Material Event - Stock Titan
Looking to Regrow Hair? New Options Are on the Horizon - WSJ
Veradermics’ stock grows on pivotal hair loss win - MSN
Is It Too Late To Consider Veradermics (MANE) After A 162% Year To Date Surge? - simplywall.st
Veradermics (MANE) sells 3.84M shares at $100; $300k-warrant PIPE - Stock Titan
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01 - Insider Monkey
[EFFECT] Veradermics, Inc SEC Filing - Stock Titan
A Look At Veradermics (MANE) Valuation After Breakthrough Phase 2/3 Results For Oral Hair Loss Drug - simplywall.st
Finanzdaten der Veradermics Inc-Aktie (MANE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):